Navigation Links
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Date:5/15/2012

and diluted$
(0.02)$
(0.02)Weighted average common shares outstanding – basic and diluted109,279,15283,097,967Non-GAAP Financial MeasureTo supplement our condensed consolidated financial statements, which statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America (GAAP), we use a non-GAAP financial measure called non-GAAP earnings or loss per share. We define non-GAAP earnings or loss per share as net income or loss not including the impact of non-cash items: stock-based compensation, change in fair value of derivative liabilities and gain on exchange of warrants.

It should be noted that basic and diluted weighted average shares are determined on a GAAP basis and the resulting share count is used for computing both GAAP and non-GAAP basic and diluted earnings per share.

With the adoption of ASC 815 and its very substantial impact on our total liabilities including certain non-cash derivative liabilities and corresponding reported net gains and losses arising from changes in the underlying market value of our common stock, we believe that non-GAAP earnings or loss per share provides meaningful supplemental information regarding our performance by excluding certain expenses that may not be indicative of the core business operating results and may help in comparing current-period results with those of prior periods as well as with our peers. We present this information to investors as an additional tool for evaluating our financial results in a manner that reflects ongoing operations and facilitates comparisons with operating results from prior periods.  The presentation of this additional non-GAAP information is intended to provide investors with additional incremental tools for their review of our results and is not meant to be considered in isolation or as a substitute for financial information presented in accordance with GAAP. 


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
5. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
6. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
7. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
8. Cardium Regains Listing Compliance With NYSE Amex
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
11. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 The Oklahoma tornado left ... ravage, the mayor of Moore, one of the heavily damaged ... a report from cnn.com. Reaching out to also be of ... and Safe Shield to counter the looming mold problem. , ... May 22, 2013, caused 24 deaths, My Cleaning Products shared. ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... January 6 Biopharmaceutical Company Kiadis,Pharma focused on ... field of bone marrow transplantation, announces today the ... (CMO). Dr. Egeler is a global,leading pediatric bone ... hemato-oncology. He brings,to Kiadis Pharma over more than ...
... Pa., Jan. 5 West Pharmaceutical Services, Inc. (NYSE: WST ... , CJS ... York City. The presentation is scheduled for 1:55pm on Wednesday, January 7, ... , Sidoti & ...
... Nektar Therapeutics,(Nasdaq: NKTR ) President and Chief ... the upcoming 27th Annual J.P. Morgan Healthcare,Conference in San ... 13, 2009 at 10:00 a.m. Pacific time (1:00 p.m. ... will be accessible via a Webcast through a link ...
Cached Biology Technology:Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer 2West to Present at Upcoming Conferences 2
(Date:5/24/2013)... and destruction by the immune system. Stimulation of the ... there are many factors that cause the immune system ... cells that function to suppress the immune system response. ... Investigation , researchers led by Ronald Levy at Stanford ... express proteins that can be targeted with therapeutic antibodies. ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery reveals ... , Within the genome of each species, there ... change in position and sequence over millions of years, ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), ... or the condensation of chromosomes, but the function of ...
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... More than one in four elderly patients was given ... of a study by Ute Amann and her co-authors ... International ( Dtsch Arztebl Int 2012; 109[5]: ... can increase the risk of undesired drug effects, and ...
... of cardiovascular pathologies seem to have a higher cancer ... published in detail in the Archives of Internal ... supplementation with B vitamins has some benefits for protecting ... in recent years remain equivocal., The results of studies ...
... Hugh Ducklow, senior scientist and director of the ... to the U.S. Antarctic Program Blue Ribbon Panel. ... Holdren, director of the White House Office of Science ... National Science Foundation, is tasked with examining the status ...
Cached Biology News:Vitamin B and omega-3 supplementation and cancer: New data 2MBL's Hugh Ducklow appointed to Antarctic Blue Ribbon Panel 2
... with a molecular weight of 16 kDa. Leptin ... produced by adipocytes [1,2]. Leptin is thought to ... weight [1-3]. In the human, leptin levels are ... [4]. A relationship between serum leptin levels and ...
... We can introduce random mutations to the ... be then cloned into a vector of choice ... Mutation frequency can be set to a ... Number of clones 106-108. Mutations can be ...
Request Info...
... plasmid DNA preparations are prepared from ... from 1mg to multi-gram scales. Each ... needs, and glycerol stocks are maintained ... clonal selection (Clonal selection includes screening ...
Biology Products: